Monthly Stock Report: Revvity, Inc. (RVTY)
Publication Date: September 22, 2024
Company Overview
Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading healthcare company focusing on innovative health sciences solutions globally, including in the Americas, Europe, and Asia. Rebranded from PerkinElmer, Inc. in April 2023, Revvity operates in the Diagnostics and Research industry. The company offers a diverse array of products and services, including advanced instruments, reagents, software, and diagnostic tools aimed at early detection of genetic disorders and infectious diseases. With a solid track record of public trading since May 31, 1985, Revvity has established itself as a key player for pharmaceutical and biotechnology firms, as well as healthcare institutions. In 2023, Revvity reported total revenues of approximately $2.71 billion, reflecting its robust performance within a competitive landscape and the industry’s promising growth potential.
Market Insights
Analysts are optimistic about Revvity’s future, setting a high price target of $185.00. This confidence in the company stems from its ability to leverage emerging market opportunities to enhance its market share in the dynamic healthcare diagnostics sector. The mean target price is currently at $135.93, signaling a favorable outlook relative to the stock’s current price of $122.89. The substantial revenue figures underscore Revvity’s significant market presence. However, while revenue metrics are favorable, there is a notable absence of EBITDA data, which raises questions about the company’s profitability.
Furthermore, Revvity currently has 123,337,000 shares outstanding, with a low short interest of 4,647,175 shares, translating to about 0.0499% of the float. This indicates a stable shareholder structure with manageable short positions. Investors may find this stability appealing, especially considering the average recommendation score of 2.2 from analysts, suggesting a prevailing sentiment to buy. The stock’s performance oscillates between a 52-week high of $128.15 and a low of $79.50, currently trading favorably above its fifty-day moving average of $118.80.
Conclusion
Investors looking to engage with the healthcare diagnostics sector may find Revvity, Inc. (RVTY) an attractive opportunity given its solid revenue base and optimistic market evaluations. With promising growth projections and a consensus buy rating from analysts, Revvity is well-positioned for potential value appreciation in the coming months. However, the absence of EBITDA figures is something that investors should monitor closely to gauge overall profitability and operational efficiency.
| Metric | Value |
|---|---|
| Market Cap | $15.2b |
| Total Debt | $4.0b |
| Total Cash | $2.0b |
| Shares Outstanding | 123.3m |
| Float Shares | 115.4m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.